
Opinion|Videos|December 21, 2023
Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases
For patients with BRAF-mutated melanoma with asymptomatic brain metastases, immunotherapy, particularly the combination of ipilimumab and nivolumab, is the preferred treatment option due to its effectiveness and durability, as supported by the seven-year follow-up data from the CHECKMATE 204 trial.
Advertisement
Advertisement
Related to this article

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5

